Answers are grounded in this paper and cite their sources.
It is increasingly clear that the nectin family and its immunoreceptors shape the immune response to cancer through several pathways. Yet, even as antibodies against TIGIT, CD96, and CD112R advance into clinical development, biological and therapeutic questions remain unanswered. Here, we review recent progress, prospects, and challenges to understanding and tapping this family in cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Johnston et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: